Core Viewpoint - Conifex Timber Inc. reported significant financial losses for the fourth quarter and the year ended December 31, 2025, with a net loss of $35.7 million for the year and negative EBITDA of $27.5 million, reflecting challenges in lumber production and increased duty rates [1][6][11]. Financial Performance - EBITDA from continuing operations was negative $12.6 million for Q4 2025 and negative $27.5 million for the full year, compared to negative EBITDA of $2.1 million in Q4 2024 and negative $13.6 million for the year [1][3]. - Net loss for 2025 was $35.7 million or negative $0.87 per share, compared to a net loss of $29.8 million or $0.73 per share in 2024 [1][3]. - Revenue from lumber products was $101.0 million in 2025, a 7% increase from 2024, driven by higher average lumber prices and increased shipment volumes [8][9]. Lumber Operations - Lumber production totaled 147.9 million board feet in 2025, reflecting an annualized operating rate of 62%, up from 134.8 million board feet in 2024 [6][7]. - Shipments of Conifex produced lumber increased by 3% to 141.1 million board feet in 2025, primarily due to higher production output earlier in the year [7][8]. - Average WSPF lumber price increased from $559 in 2024 to $651 in 2025, a 16% rise, despite market volatility and increased duty rates [9][10]. Cost Structure - Cost of goods sold increased by 6% in 2025, primarily due to higher production volumes and a $3.0 million non-cash inventory write-down in Q4 [10][11]. - Selling, general and administrative costs decreased by 19% to $5.8 million in 2025, attributed to lower salaries and benefits costs [18]. - Finance costs and accretion rose by 59% to $12.7 million in 2025, mainly due to higher interest expenses from additional draws under the Pender Term Loan [19]. Bioenergy Operations - The Power Plant sold 179.0 GWh of electricity in 2025, contributing revenues of $25.6 million, an 8% increase from 2024 [16][17]. - Electricity production was approximately 80% of targeted operating rates, reflecting improved operational availability [16]. Market Conditions and Outlook - The North American lumber market experienced volatility due to elevated duty deposit rates and tariff uncertainty, impacting production and pricing [9][11]. - Future cash flows may be adversely affected by the combined duty and tariff rate of 45.16% on US-bound shipments, constraining operating margins [49]. - The company anticipates a potential reduction in duty rates in Q4 2026 and expects a recovery in softwood lumber pricing and demand over the medium term [50][58].

Core Insights - Damora Therapeutics has appointed Jennifer Jarrett as President and CEO, effective March 30, 2026, bringing nearly three decades of experience in biotech, tech, and finance [1][2] - The company aims to redefine care for patients with blood disorders, particularly focusing on mutant calreticulin-driven myeloproliferative neoplasms (MPNs) [2][7] - The Board of Directors has also appointed Cameron Turtle and Mike Landsittel, enhancing the board's expertise in biotech and capital markets [3][4] Company Leadership - Jennifer Jarrett has a strong background in corporate strategy, finance, and drug development, previously serving as COO of Arcus Biosciences and CFO of Medivation [2][5] - Peter Harwin has been named Chairman of the Board, emphasizing the strategic direction of the company [3][4] - Cameron Turtle and Mike Landsittel bring extensive experience in building and leading biotech companies, with Turtle focusing on development and commercialization and Landsittel on strategic finance [5][6] Strategic Focus - Damora is advancing a portfolio of potential best-in-class therapies aimed at treating MPNs, with plans to enter clinical development in 2026 [7] - The company is positioned to rapidly develop its lead program, DMR-001, while also advancing additional pipeline assets [2][7] - The board acknowledges the contributions of departing directors, highlighting the strategic importance of recent transactions [5]

Core Viewpoint - Nano Labs Ltd will report its unaudited financial results for the six months ended December 31, 2025, on March 30, 2026, before the U.S. market opens [1] Group 1: Financial Reporting - The earnings conference call will take place at 8:30 am U.S. Eastern Time on March 30, 2026 [1] - Participants can register for the call through a provided link and will receive a unique PIN for access [2] - A live and archived webcast of the conference call will be available on the Company's investor relations website [3] Group 2: Company Overview - Nano Labs Ltd is a leading provider of Web 3.0 infrastructure and product solutions [4] - The Company focuses on developing high throughput computing (HTC) chips and high performance computing (HPC) chips [4] - Nano Labs has established a comprehensive flow processing unit (FPU) architecture that integrates features of both HTC and HPC [4] - The Company has positioned itself in the crypto assets space, adopting BNB as its primary reserve asset and covering multiple business verticals [4]

Core Viewpoint - Byrna Technologies Inc. will hold a conference call on April 9, 2026, to discuss its financial results for the fiscal first quarter ended February 28, 2026 [1] Group 1: Conference Call Details - The conference call is scheduled for Thursday, April 9, 2026, at 9:00 a.m. Eastern time [2] - Participants can join the call using a toll-free number or an international dial-in number, and should call 10 minutes prior to the start time for registration [2] - The call will be broadcast live and available for replay on Byrna's website [3] Group 2: Company Overview - Byrna Technologies Inc. specializes in the development, manufacture, and sale of innovative less-lethal personal security solutions [4] - The company produces the Byrna CL, Byrna LE, and Byrna SD personal security devices, which are CO2 powered launchers designed as less-lethal alternatives to firearms [4]

Group 1 - WTW has appointed Hazel Rees as the Global Leader of its Work & Rewards business, effective June 1, 2026 [1] - Rees has extensive leadership experience, having led WTW's European Work & Rewards business since 2021 and has a strong track record in areas such as executive pay and pay transparency [2] - She succeeds Mark Reid, who has led the business for the past eight years and will return to advising clients directly while taking on special initiatives [3] Group 2 - Julie Gebauer, President of Health, Wealth & Career at WTW, highlighted Mark Reid's contributions in building tech capabilities and integrating data with advisory services [4] - Mark Reid expressed confidence in Hazel Rees's ability to evolve the business to meet client needs [4] - WTW provides data-driven solutions in people, risk, and capital across 140 countries, aiming to enhance organizational resilience and performance [5]

Core Viewpoint - Rezolve Ai is set to release its financial results for the second half and full year ended December 31, 2025, on March 30, 2026, indicating a period of significant commercial progress and expansion in its global commerce infrastructure platform [1][2]. Group 1 - The financial results announcement will occur before market open on March 30, 2026, followed by a live conference call at 8:30 a.m. Eastern Time to discuss the results and provide a business update [1]. - The 2025 results are anticipated to show accelerated enterprise deployment and continued expansion of Rezolve's global commerce infrastructure platform [2]. Group 2 - The live webcast of the conference call will be accessible on Rezolve Ai's Investor Relations website, with registration required via the provided link [3]. - A replay of the webcast will be available after the conclusion of the call [3]. Group 3 - Rezolve Ai is focused on building the infrastructure layer for AI-driven commerce through its Brain Suite platform, enabling real-time consumer engagement and transaction execution via AI-powered systems [4].

Core Insights - NewAmsterdam Pharma is presenting data on obicetrapib, a novel oral low-dose therapy for hypercholesterolemia, at the American College of Cardiology Annual Scientific Session [1] Group 1: Presentation Details - The presentation titled "CETP Inhibition with Obicetrapib Preserved Kidney Function in Patients at High Cardiovascular Risk: Results from the BROADWAY Trial" will take place on March 28, 2026 [2] - Another presentation titled "Safety of Obicetrapib: An Integrated Pooled Phase III Safety Analysis" is scheduled for March 29, 2026 [2] - A third presentation titled "Cardiovascular Events in People with Normal Low-Density Lipoprotein Cholesterol Levels but Discordantly High Levels of Small/Medium LDL Particles" will occur on March 30, 2026 [2] Group 2: About Obicetrapib - Obicetrapib is a CETP inhibitor developed to address limitations of current LDL-lowering treatments, showing statistically significant LDL-lowering effects in multiple Phase 2 and Phase 3 trials [3] - The Phase 3 PREVAIL trial, assessing obicetrapib's potential to reduce major adverse cardiovascular events (MACE), completed enrollment with over 9,500 patients [3] - Commercialization rights for obicetrapib in Europe have been granted to the Menarini Group [3] Group 3: About NewAmsterdam - NewAmsterdam Pharma focuses on improving patient care for metabolic diseases where existing therapies are inadequate or poorly tolerated [4] - The company is investigating obicetrapib as a once-daily CETP inhibitor, either alone or in combination with ezetimibe, for patients at risk of cardiovascular disease [4]

Core Viewpoint - Reviva Pharmaceuticals Holdings, Inc. has successfully closed a public offering, raising approximately $10 million to fund its research and development activities, particularly for its Phase 3 trial of brilaroxazine in schizophrenia [1][3]. Group 1: Offering Details - The company offered 6,666,667 shares of common stock along with Series G and Series H warrants, each with an exercise price of $1.50 per share [1][2]. - The Series G Warrants are exercisable immediately and expire five years from the issuance date, while the Series H Warrants are also exercisable immediately but expire 12 months from the issuance date [2]. Group 2: Use of Proceeds - The net proceeds from the offering, combined with existing cash and cash equivalents, will be used to fund research and development activities, including the planned RECOVER-2 Phase 3 trial for brilaroxazine, as well as for working capital and other general corporate purposes [3]. Group 3: Financial Position - Following the offering, the company has approximately $23 million in cash and cash equivalents, which is expected to fund operations into Q1-2027 [4]. Group 4: Company Overview - Reviva is a late-stage biopharmaceutical company focused on developing therapies for unmet medical needs in CNS, inflammatory, and cardiometabolic diseases, with a pipeline that includes brilaroxazine and RP1208 [7].

Core Viewpoint - Oncotelic Therapeutics, through its subsidiary Sapu Nano, is presenting new findings on everolimus toxicology at the Society of Toxicology 2026 Annual Meeting, emphasizing the significance of tissue concentration in determining organ-specific toxicological outcomes [1][2][3]. Group 1: Presentation Details - The presentation titled "Everolimus Toxicology: Tissue Concentration Effects" will be featured during the Poster Session: ADME/Toxicokinetics I [2]. - Authors of the presentation include W. Chang, N. Chang, T. Hoque, and C. Lee from Sapu Nano, San Diego, CA [2]. - The findings aim to advance understanding of the relationship between tissue-level exposure of everolimus and its toxicological effects, moving beyond traditional plasma pharmacokinetics [2]. Group 2: Significance of Findings - The data presented highlight the importance of tissue pharmacokinetics in determining toxicity profiles for mTOR inhibitors like everolimus [3]. - These findings provide a foundation for developing improved drug delivery strategies, including intravenous and nanoparticle-based formulations that enhance control over biodistribution [3][4]. Group 3: Company Background - Oncotelic Therapeutics, originally formed as OXiGENE, Inc. in 1988, focuses on oncology drug development, particularly for rare pediatric cancers [6]. - The company has a joint venture for Diffuse Intrinsic Pontine Glioma (DIPG) and is also involved in developing treatments for melanoma and Acute Myeloid Leukemia (AML) [6]. - Sapu Nano is dedicated to developing next-generation nanomedicine platforms aimed at improving drug delivery and enhancing therapeutic indices [5].

Core Insights - TTEC has appointed Chris Brown as president of TTEC Digital, effective immediately, succeeding David Seybold who will depart on April 30, 2026 [1][2] - Brown's leadership is expected to drive TTEC Digital's global strategy, P&L management, and operational execution, leveraging his extensive experience and institutional knowledge [2][3] Leadership Transition - David Seybold will remain with TTEC until April 30, 2026, to ensure a smooth transition [2] - Chris Brown has been with TTEC since 2015 and previously served as Chief of Staff to the Chairman and CEO, focusing on corporate development and strategic partnerships [3][4] Chris Brown's Background - Brown has over two decades of experience advising technology and services firms on M&A, capital markets, and strategic transformation, with a focus on SaaS, AI, and cloud sectors [4] - He has held senior leadership roles in investment banking at UBS and management consulting at Mercer, and played a key role in the acquisition of Liquid Robotics by Boeing [4] TTEC Digital's Vision - Brown emphasized the unique capabilities of TTEC Digital in combining talent, technology partnerships, and AI expertise to deliver value for enterprise clients globally [5] - TTEC Digital is recognized as the world's largest pureplay CX technology and services provider, enhancing customer engagement and operational efficiency [5][6] Company Overview - TTEC Holdings, Inc. is a global consulting, technology, and managed services company focused on data, AI, and customer experience [6] - The company offers outcome-based solutions that span the entire enterprise and improve customer interactions across various channels [6]